Rebecca Burdine is a Professor in the Department of Molecular Biology at Princeton University. Her lab focuses on understanding the developmental mechanisms that control organ morphogenesis and underlie structural birth defects and rare genetic disorders. She was named the 44th Mallinckrodt Scholar for the Edward Mallinckrodt Jr. Foundation and received a Scientist Development Career Award from the American Heart Association in 2003. She was elected as fellow to the American Association for the Advancement of Science (AAAS) in 2018.
Dr. Burdine is mom to Sophie, Del+ AS. She first served on the Angelman Syndrome Foundation (ASF) scientific advisory committee by invitation from Dr. Joe Wagstaff in 2007. She is currently on the Board of Directors for ASF and is Chair of the Scientific Advisory Committee. She previously served as a founding Board member and Chief Scientific Officer for the Foundation for Angelman Syndrome Therapeutics and as Chief Scientific Officer for the Pitt-Hopkins Research Foundation. Dr. Burdine also served as a patient representative on the Clinical Trial Steering Committee for the STARS and NEPTUNE studies conducted by Ovid Therapeutics for AS.